THERALASE TECHNOLOGIES INC (TLT.CA) Stock Price, Forecast & Analysis

TSX-V:TLT • CA88337V1004

0.275 CAD
+0.01 (+1.85%)
Last: Feb 23, 2026, 07:00 PM

TLT.CA Key Statistics, Chart & Performance

Key Statistics
Market Cap70.69M
Revenue(TTM)1.00M
Net Income(TTM)-4.35M
Shares257.06M
Float236.51M
52 Week High0.36
52 Week Low0.14
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.02
PEN/A
Fwd PEN/A
Earnings (Next)03-10
IPO2004-11-02
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
TLT.CA short term performance overview.The bars show the price performance of TLT.CA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 40 60

TLT.CA long term performance overview.The bars show the price performance of TLT.CA in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 20 -20

The current stock price of TLT.CA is 0.275 CAD. In the past month the price increased by 7.84%. In the past year, price increased by 7.84%.

THERALASE TECHNOLOGIES INC / TLT Daily stock chart

TLT.CA Technical Analysis

ChartMill assigns a technical rating of 7 / 10 to TLT.CA. When comparing the yearly performance of all stocks, TLT.CA is one of the better performing stocks in the market, outperforming 74.53% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
TLT.CA Full Technical Analysis Report

TLT.CA Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to TLT.CA. TLT.CA may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
TLT.CA Full Fundamental Analysis Report

TLT.CA Financial Highlights

Over the last trailing twelve months TLT.CA reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 23.81% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -144.9%
ROE -398.4%
Debt/Equity 0.19
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%-19.6%
EPS 1Y (TTM)23.81%
Revenue 1Y (TTM)1.45%
TLT.CA financials

TLT.CA Forecast & Estimates

9 analysts have analysed TLT.CA and the average price target is 0.71 CAD. This implies a price increase of 159.64% is expected in the next year compared to the current price of 0.275.

For the next year, analysts expect an EPS growth of 39.41% and a revenue growth 13.84% for TLT.CA


Analysts
Analysts84.44
Price Target0.71 (158.18%)
EPS Next Y39.41%
Revenue Next Year13.84%
TLT.CA Analyst EstimatesTLT.CA Analyst Ratings

TLT.CA Ownership

Ownership
Inst Owners0%
Ins Owners2.83%
Short Float %N/A
Short RatioN/A
TLT.CA Ownership

TLT.CA Competitors/Peers

The largest stocks on the Canadian markets in the "Health Care Equipment" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
PRN PROFOUND MEDICAL CORP N/A348.021M
CNVI CONAVI MEDICAL CORP N/A38.783M
PINK PERIMETER MEDICAL IMAGING AI N/A36.714M
ASG AURORA SPINE CORP N/A22.008M
VPT VENTRIPOINT DIAGNOSTICS LTD N/A21.433M
NSCI NANALYSIS SCIENTIFIC CORP N/A20.768M
MDX MEDX HEALTH CORP N/A19.676M
THRM THERMA BRIGHT INC N/A3.125M
IDL IMAGING DYNAMICS CO LTD N/A929.7K

About TLT.CA

Company Profile

TLT logo image Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. The company is headquartered in Toronto, Ontario. The company went IPO on 2004-11-02. The firm is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. The company operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.

Company Info

THERALASE TECHNOLOGIES INC

41 Hollinger Road

TORONTO ONTARIO M4B 3G4 CA

CEO: Shawn Shirazi

Employees: 20

TLT Company Website

TLT Investor Relations

Phone: 14166995273

THERALASE TECHNOLOGIES INC / TLT.CA FAQ

What does THERALASE TECHNOLOGIES INC do?

Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. The company is headquartered in Toronto, Ontario. The company went IPO on 2004-11-02. The firm is engaged in the research and development of light, radiation, sound and drug-activated small molecule compounds and their associated formulations, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses, with minimal impact on surrounding healthy tissue. The company operates through two divisions: the Drug Division and the Device Division. The Drug Division is responsible for the research and development of small molecules primarily for the treatment of cancer with assistance from the Device Division to develop medical lasers to activate them. The Device Division is responsible for the Company’s medical laser business, which researches, develops, manufactures and distributes cool laser therapy systems to healthcare practitioners, predominantly for the healing of pain.


What is the current price of TLT stock?

The current stock price of TLT.CA is 0.275 CAD. The price increased by 1.85% in the last trading session.


Does TLT stock pay dividends?

TLT.CA does not pay a dividend.


What is the ChartMill rating of THERALASE TECHNOLOGIES INC stock?

TLT.CA has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


What is the Price/Earnings (PE) ratio of THERALASE TECHNOLOGIES INC (TLT.CA)?

THERALASE TECHNOLOGIES INC (TLT.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.02).


Can you provide the market cap for THERALASE TECHNOLOGIES INC?

THERALASE TECHNOLOGIES INC (TLT.CA) has a market capitalization of 70.69M CAD. This makes TLT.CA a Micro Cap stock.